SCHEMBL5831094

SCHEMBL5831094

O=C(Cc1nsc(NS(=O)(=O)c2c(Cl)cc(Cl)cc2Cl)n1)N1CCSCC1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.56
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CNR1 P21554 3/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
SCN9A Q15858 1/20 0.34
ALDH1A1 P00352 1/20 0.33
SLC40A1 Q9NP59 1/20 0.33
F10 P00742 1/20 0.33
RORC P51449 1/20 0.32
JAK1 P23458 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831698 0.93 HSD11B1 (0.49) HSD11B1HSD17B1HSD17B2NPC1RAB9A
SCHEMBL5831436 0.91 HSD11B1 (0.56) HSD11B1HSD17B1HSD17B2NPC1RAB9A
SCHEMBL6930698 0.90 HSD11B1 (0.47) HSD11B1HSD17B1HSD17B2NPC1RAB9A
SCHEMBL5830689 0.89 HSD11B1 (0.71) HSD11B1HSD17B1HSD17B2KDM4EMEN1
SCHEMBL5830658 0.84 HSD11B1 (0.50) HSD11B1HSD17B1HSD17B2NPC1RAB9A
SCHEMBL6930704 0.83 HSD11B1 (0.41) HSD11B1
SCHEMBL5830857 0.82 HSD11B1 (0.62) HSD11B1HSD17B1HSD17B2RAB9AKDM4E
SCHEMBL3605392 0.82 HSD11B1 (0.80) HSD11B1HSD17B1HSD17B2MEN1MAPT
SCHEMBL5830973 0.81 HSD11B1 (0.53) HSD11B1HSD17B1HSD17B2MEN1KMT2A
SCHEMBL5831449 0.81 HSD11B1 (0.59) HSD11B1HSD17B1HSD17B2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HSD11B1 2/4885HSD17B1 5/4885HSD17B2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.